Chinese scientists found that the new discovery is expected to achieve early det

        Newspaper in Beijing on 19 October, (China youth - Youth Online reporter Zhuge Yahan) Tsinghua University today held a press conference to announce that Professor Luo Yongzhang of the College of life science and the team for the first time in the world that tumor markers of heat shock protein 90 alpha (Hsp90 alpha) can be used in the detection of liver cancer patients, has been approved by the State Administration of food and drug supervision management in clinical use.

        Tsinghua University vice president Xue Qikun said, "this marks the first by the Chinese scientists and approved for clinical definition, broad-spectrum tumor marker was born, has the profound significance to improve the level of diagnosis and treatment of cancer".

        According to reports, the tumor markers are able to reflect the existence and growth of a class of tumors. Usually, it is far more than the healthy people in the content in tumor patients. The examination is simple, damage to the body small, only need a small amount of blood or other body fluids can detect cancer early trail, has become an important tool widely used in clinical practice.

        Most of the liver cancer patients found to have been to the middle and advanced stage, survival is expected to generally poor. "2015 Chinese cancer statistics report" shows that last year China's 4 million 292 thousand new cancer cases, 2 million 814 thousand deaths, the incidence of liver cancer accounted for 12% of the total cancer incidence and mortality rate of cancer mortality accounted for the total 16%, are located in the forefront of various types of cancer.

        AFP is recognized as a marker for liver cancer detection, but its sensitivity is only about 50%. "The new tumor marker alpha Hsp90 broke through the limitation of AFP, a sensitivity of about AFP times higher than that of AFP negative patients with liver cancer; diagnosis coincidence rate was 94% for AFP diagnosis and early diagnosis of hepatocellular carcinoma is limited; the coincidence rate is 91%, is expected to achieve early detection and early treatment of liver cancer." "." Luo Yongzhang said.

        There is a good correlation between the occurrence and progress of plasma Hsp90 concentration and liver cancer, and liver cancer by pathological type limitations, sensitivity of hepatocellular carcinoma and intrahepatic bile duct cancer, liver cancer and other common types of mixed hepatocellular carcinoma were high, provides an important basis for the early diagnosis of hepatocellular carcinoma for detection. In addition, there is much correspondence between the changes of plasma Hsp90 concentrations in patients with the patient's condition changes, this evaluation, disease monitoring and treatment of patients with hepatocellular carcinoma tumor timely guide individualized treatment has important clinical value.

        Up to now, the Luo Yongzhang team developed a Hsp90 alpha quantitative detection kit is Hsp90 alpha was found in 27 years the world's only approved for clinical products. The kit has been awarded the national third categories (highest category) medical device certificate, and through the EU certification, access to domestic and foreign counterparts of the high evaluation.